In our in vitro study, low-dose decitabine was found to decrease the levels of p-PI3K and p-AKT, suggesting that the inhibitory effect of low-dose decitabine on CD8+ T cells might be related to PI3K/AKT signaling pathway in ITP. Here, CD8A is linked to autoimmune thrombocytopenic purpura.